Volume No : (2021) Volume: 09 Issue : 44 Year : 2021 Page No: 69-75
Authors : Shridhar Pandya, Chetan Savaliya, Gayatri Ganu, Kamlesh Thummar, Amar Raykantiwar, Abhijit Shekhar
Abstract :
Aim: This study aims to study theeffectiveness of Gplife advanced diabetic support tablet as adjuvant therapy inpatients with diabetes mellitus. Materials and Methods: The study wasconducted as a single-arm, a prospective clinical trial at two sites, fastingplasma glucose (FPG), post-meal glucose (PMG), and glycated hemoglobin (HbA1c)were evaluated till 60 days in 30 diabetic subjects. Results: Initially,the levels of mean FPG were 344.70 ± 80.12 mg/dL, for day 60, it was reduced to155.80 ± 31.44 mg/dL. At the baseline visit, the mean PMG level was 436.22 ±102.73 mg/dL, for day 60, it was reduced to 204.87 ± 27.74 mg/dL and HbA1C %was 10.35 ± 1.95, for day 60, it was reduced to 7.34 ± 0.97 mg/dL. There was areduction in clinical symptoms of diabetes. Treatment caused a reduction indoses of insulin and oral hypoglycemic agents in the test population at 60days. Conclusion: It can be concluded that adjuvant therapy of Gplifeadvanced diabetic support tablet is significantly effective in reducing levelsof FPG and PMG from baseline to 60 days. The change was not significant in anyof the safety parameters suggesting safety. It showed a reduction in existingdoses of conventional treatment hence can be used as an adjuvant in diabetes.
Full Text PDF